Literature DB >> 19485567

Effects of the first prepulse on the blink response to a startling noise.

Neal R Swerdlow1, Jo A Talledo.   

Abstract

Startle is inhibited when a startling stimulus follows 30-300 ms after a weak prepulse. Prepulse inhibition (PPI) is an operational measure of sensorimotor gating and is deficient in several neuropsychiatric disorders. Previous reports argue both for and against a learned component to the inhibitory effects of prepulses, but this issue has yet to be fully investigated using stimuli that most commonly detect PPI deficits in clinical populations. If the inhibitory impact of a prepulse is learned, PPI should not be evident when the prepulse is the first stimulus experienced by the subject. Eyeblink electromyography in normal adults was recorded after either a 118 dB(A) 40-ms noise pulse alone (PA) or the same pulse preceded 120 ms by an 86 dB(A) 5-ms noise prepulse (pp+P). In 25 subjects (Order 1), Trial 1 was a PA, and Trial 2 was a pp+P; 23 subjects experienced the opposite order (Order 2). In 34 subjects, Trials 1 and 2 were both PA (control order). Background was 70 dB(A). Startle magnitude increased from Trial 1 to 2 if no prepulse was presented (control order). Compared with the control order, startle inhibition by prepulses was evident in both Orders 1 and 2, and was more robust in Order 2 (first trial=pp+P). Startle magnitude was significantly lower on pp+P than on PA trials in Order 2 but not Order 1 (F<1). Prepulses inhibit startle on the first pairing with a startling pulse, an effect that cannot be explained by learning. Copyright (c) 2009 APA, all rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19485567      PMCID: PMC5944322          DOI: 10.1037/a0015064

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  23 in total

1.  Presidential Address, 1974. The more or less startling effects of weak prestimulation.

Authors:  F K Graham
Journal:  Psychophysiology       Date:  1975-05       Impact factor: 4.016

2.  Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication.

Authors:  V Kumari; W Soni; V M Mathew; T Sharma
Journal:  Arch Gen Psychiatry       Date:  2000-06

3.  Lower prepulse inhibition in children with the 22q11 deletion syndrome.

Authors:  Christina Sobin; Karen Kiley-Brabeck; Maria Karayiorgou
Journal:  Am J Psychiatry       Date:  2005-06       Impact factor: 18.112

4.  Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders.

Authors:  N R Swerdlow; P L Hartman; P P Auerbach
Journal:  Biol Psychiatry       Date:  1997-02-15       Impact factor: 13.382

5.  Symptom correlates of prepulse inhibition deficits in male schizophrenic patients.

Authors:  D L Braff; N R Swerdlow; M A Geyer
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

6.  Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder.

Authors:  Klaus Hoenig; Andrea Hochrein; Boris B Quednow; Wolfgang Maier; Michael Wagner
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

7.  Normalization of information processing deficits in schizophrenia with clozapine.

Authors:  V Kumari; W Soni; T Sharma
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

Review 8.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

10.  Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia.

Authors:  Katja Ludewig; Mark A Geyer; Franz X Vollenweider
Journal:  Biol Psychiatry       Date:  2003-07-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.